CN102459639A - 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法 - Google Patents

用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法 Download PDF

Info

Publication number
CN102459639A
CN102459639A CN201080027267XA CN201080027267A CN102459639A CN 102459639 A CN102459639 A CN 102459639A CN 201080027267X A CN201080027267X A CN 201080027267XA CN 201080027267 A CN201080027267 A CN 201080027267A CN 102459639 A CN102459639 A CN 102459639A
Authority
CN
China
Prior art keywords
seq
sample
antibody
expression level
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080027267XA
Other languages
English (en)
Chinese (zh)
Inventor
D.多南
B.伯林顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN102459639A publication Critical patent/CN102459639A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201080027267XA 2009-04-18 2010-04-17 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法 Pending CN102459639A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17061509P 2009-04-18 2009-04-18
US61/170,615 2009-04-18
PCT/US2010/031528 WO2010121231A1 (en) 2009-04-18 2010-04-17 Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
CN102459639A true CN102459639A (zh) 2012-05-16

Family

ID=42358184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080027267XA Pending CN102459639A (zh) 2009-04-18 2010-04-17 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法

Country Status (12)

Country Link
US (1) US9617600B2 (enExample)
EP (1) EP2419531B1 (enExample)
JP (1) JP5836929B2 (enExample)
KR (1) KR101787768B1 (enExample)
CN (1) CN102459639A (enExample)
AU (1) AU2010236168B2 (enExample)
BR (1) BRPI1011394A8 (enExample)
CA (1) CA2758523C (enExample)
ES (1) ES2605228T3 (enExample)
IL (1) IL215707A (enExample)
MX (1) MX2011010938A (enExample)
WO (1) WO2010121231A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820707A2 (pt) 2007-11-07 2015-06-16 Genentech Inc Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
ES2634254T3 (es) 2011-09-12 2017-09-27 Atrys Health, SA Métodos para el pronóstico del linfoma difuso de linfocitos B grandes
HUE049569T2 (hu) 2012-08-09 2020-09-28 Celgene Corp Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
TWI794885B (zh) 2014-05-19 2023-03-01 美商西建公司 全身紅斑性狼瘡之治療
JP2018529344A (ja) * 2015-09-25 2018-10-11 セルジーン コーポレイション びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
WO2022120038A1 (en) * 2020-12-02 2022-06-09 Albert Einstein College Of Medicine Method for predicting patient response to cd40-targeted therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910414A (zh) * 2007-11-07 2010-12-08 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002078766A2 (en) 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗ｃｄ４０モノクローナル抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
RS53073B (sr) 2003-11-04 2014-04-30 Novartis Vaccines And Diagnostics Inc. Upotreba antagonističkih anti-cd40 monoklonska antitela
SI1682177T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
CA2848463A1 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
JP5421590B2 (ja) * 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
ATE485057T1 (de) * 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
JP5904569B2 (ja) * 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
JP2009508484A (ja) * 2005-09-16 2009-03-05 バイオベイター・テクノロジーズ・アクチボラゲット アレルゲン性タンパク質の同定のためのインビトロアッセイ
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
MX2008007140A (es) 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
US7527774B2 (en) 2005-12-22 2009-05-05 Basf Catalysts Llc Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms
EP1987161A4 (en) * 2006-01-20 2009-06-24 Univ Mcgill METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS
RU2473555C2 (ru) 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910414A (zh) * 2007-11-07 2010-12-08 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEAN P.BOHEN ET AL.: "Variation in gene expression patterns in follicular lymphoma and the response to rituximab", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENSES OF THE UNITED STATES OF AMERICA》 *
SHI XIAOYAN ET AL.: "Indentification of a diagnostic gene signature for SGN-40, anti-CD40 monoclonal antibody, in pre-clinical NHL models and the role of FAS in SGN-40 Mediated Apoptosis", 《BLOOD》 *

Also Published As

Publication number Publication date
CA2758523C (en) 2019-03-12
MX2011010938A (es) 2012-01-12
JP5836929B2 (ja) 2015-12-24
US9617600B2 (en) 2017-04-11
WO2010121231A1 (en) 2010-10-21
AU2010236168A1 (en) 2011-11-10
BRPI1011394A2 (pt) 2016-03-15
IL215707A0 (en) 2012-01-31
IL215707A (en) 2016-08-31
US20120123695A1 (en) 2012-05-17
ES2605228T3 (es) 2017-03-13
AU2010236168B2 (en) 2015-08-13
EP2419531A1 (en) 2012-02-22
CA2758523A1 (en) 2010-10-21
KR20120013992A (ko) 2012-02-15
JP2012523838A (ja) 2012-10-11
BRPI1011394A8 (pt) 2018-06-26
EP2419531B1 (en) 2016-09-07
KR101787768B1 (ko) 2017-10-18

Similar Documents

Publication Publication Date Title
CN101910414B (zh) 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
CN106086175B (zh) 用于检测自身免疫性病症的方法和组合物
EP2419531B1 (en) Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
JP5996429B2 (ja) 関節リウマチの治療、診断及びモニターするための方法
JP2013503643A5 (enExample)
US20070092890A1 (en) Methods and compositions for detecting autoimmune disorders
AU2013202908A1 (en) Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
HK1231131A1 (en) Methods and compositions for detecting autoimmune disorders
HK1231131B (zh) 用於檢測自身免疫性病症的方法和組合物
EA043425B1 (ru) Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120516